Registry for Pancreatic Cancer
NCT03001505 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2017-12-06
Summary
This is an observational, prospective and retrospective registry of patients with pancreatic cancer treated in Duke University Health System, which will examine patient and treatment effects on cancer outcomes.
Conditions
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Sabino Zani, MD · DUHS
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-05-04
- Primary Completion
- 2037-04-30
- Completion
- 2037-04-30
Countries
- United States
Study Locations
More Related Trials
-
Impact of Nationwide Enhanced Implementation of Best Practices in Pancreatic Cancer Care (PACAP-1)
NCT03513705 ·Status: COMPLETED ·Phase: NA
-
Pancreatic Enzyme Suppletion in Pancreatic Cancer
NCT01401387 ·Status: WITHDRAWN ·Phase: PHASE4
-
Development & Clinical Application of K-PaC Registry Version 2.0
NCT07171515 ·Status: ENROLLING_BY_INVITATION
-
Positron Emission Tomography Using [18F]-Labeled Substance P Antagonist Receptor Quantifier in Finding Disease in Patients With Pancreatic Cancer
NCT00547612 ·Status: COMPLETED ·Phase: PHASE1
-
Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer
NCT02318095 ·Status: COMPLETED ·Phase: NA
-
Study of Gemcitabine Chemoradiation and TNP-470 Patients Locally Advanced, Nonmetastatic Adenocarcinoma of Pancreas
NCT00038701 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or TH-302 Placebo
NCT02496832 ·Status: WITHDRAWN ·Phase: NA
-
A Study of Pancreatic Cancer in Xenografts From Liver Metastases
NCT01774643 ·Status: COMPLETED
-
Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy
NCT03060720 ·Status: ACTIVE_NOT_RECRUITING
-
Pancreas Registry and High Risk Registry
NCT02775461 ·Status: RECRUITING
-
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
NCT06151223 ·Status: RECRUITING
-
Pilot, Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery, Adenocarcinoma of the Pancreas
NCT01783054 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis
NCT02869802 ·Status: RECRUITING
-
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer
NCT00025168 ·Status: COMPLETED ·Phase: PHASE2
-
Predicting Effective Therapy in Pancreatic Cancer
NCT03033927 ·Status: ACTIVE_NOT_RECRUITING
-
Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients
NCT01198522 ·Status: TERMINATED ·Phase: PHASE1
-
Immunologic Signatures Following Surgery for Pancreatic Cancer
NCT03001518 ·Status: COMPLETED
-
SERum-bank for PANcreatic Cancer
NCT04374175 ·Status: RECRUITING
-
HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma
NCT02850874 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of Changes and Characteristics of Genes in Patients With Pancreatic Cancer for Better Treatment Selection
NCT02750657 ·Status: COMPLETED
-
Influence Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic Cancer
NCT05201729 ·Status: UNKNOWN
-
Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer
NCT00320749 ·Status: COMPLETED ·Phase: PHASE1
-
Collecting and Storing Samples of Blood From Patients With Pancreatic Cancer and Healthy Participants
NCT00898482 ·Status: COMPLETED
-
Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer
NCT01080248 ·Status: TERMINATED ·Phase: PHASE2
-
RNA Precision Oncology in Advanced Pancreatic Cancer
NCT04476537 ·Status: TERMINATED ·Phase: NA